Skip to content

Tinidazole

Nitroimidazole Antimicrobial — ALIMENTARY TRACT AND METABOLISM

Also known as: tindamax, tinidazol, trimonase

OfpFDA approvedOrphan designationATC A02BD09ATC G01AF21ATC J01RA11

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Tinidazole is an ofp drug in the Nitroimidazole Antimicrobial class catalogued in DrugCentral. It was first approved by the FDA in 2004. Recorded indications include Acute amebiasis, Amebic liver abscess, Bacterial vaginosis and Giardiasis.

  • Approval status: ofp (first approved 2004 by the FDA).
  • Drug class: Nitroimidazole Antimicrobial.
  • Indications: Acute amebiasis, Amebic liver abscess, Bacterial vaginosis, Giardiasis and Infection by Trichomonas.
  • ATC code: A02BD09 (Combinations for eradication of Helicobacter pylori).
  • Molecular formula: C8H13N3O4S; molecular weight 247.27 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (5)

  • Acute amebiasis
  • Amebic liver abscess
  • Bacterial vaginosis
  • Giardiasis
  • Infection by Trichomonas

Contraindications (4)

  • Breastfeeding (mother)
  • Epilepsy
  • Neutropenic disorder
  • Peripheral nerve disease

Mechanism & targets

Established pharmacologic classNitroimidazole Antimicrobial

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2004-05-17FDA—MISSION PHARMAYes

ATC classification

ATC codeTherapeutic hierarchy
A02BD09ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › Combinations for eradication of Helicobacter pylori
G01AF21GENITO URINARY SYSTEM AND SEX HORMONES › GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS › ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS › Imidazole derivatives
J01RA11ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › COMBINATIONS OF ANTIBACTERIALS › Combinations of antibacterials
J01RA13ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › COMBINATIONS OF ANTIBACTERIALS › Combinations of antibacterials
J01RA18ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › COMBINATIONS OF ANTIBACTERIALS › Combinations of antibacterials
J01XD02ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER ANTIBACTERIALS › Imidazole derivatives
P01AB02ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES › Nitroimidazole derivatives
P01AB53ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES › Nitroimidazole derivatives

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Tinidazole is on its molecule page.

Molecular formulaC8H13N3O4S
Molecular weight247.27 g/mol
CAS number19387-91-8
InChIKeyHJLSLZFTEKNLFI-UHFFFAOYSA-N
PubChem CID5479
CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Tinidazole used for?

DrugCentral lists the following indications for Tinidazole: Acute amebiasis, Amebic liver abscess, Bacterial vaginosis, Giardiasis and Infection by Trichomonas.

When was Tinidazole first approved?

Tinidazole was first approved by the FDA in 2004.

What drug class does Tinidazole belong to?

Tinidazole is in the Nitroimidazole Antimicrobial class.

What is the chemical formula of Tinidazole?

Tinidazole has the molecular formula C8H13N3O4S and a molecular weight of 247.27 g/mol.

Browse: all drugs starting with T · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval2004-05-17
AgencyFDA
Targets0
Indications5
FormulaC8H13N3O4S
DrugCentral ID2671
Interactive profile